When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Alzheimer disease

Last reviewed: 25 Nov 2025
Last updated: 12 Nov 2025

Summary

Definition

História e exame físico

Principais fatores diagnósticos

  • memory loss
  • disorientation
  • nominal dysphasia
  • misplacing items/getting lost
  • apathy
  • decline in activities of daily living and instrumental activities of daily living (IADLs)
  • personality change
  • unremarkable initial physical exam
Detalhes completos

Outros fatores diagnósticos

  • mood and behavior changes
  • poor abstract thinking
  • constructional dyspraxia
  • prosopagnosia
  • autoprosopagnosia
Detalhes completos

Fatores de risco

  • advanced age
  • family history
  • genetics
  • Down syndrome
  • cerebrovascular disease
  • lifestyle factors and environment
  • use of certain drugs
  • less than high school education
  • traumatic brain injury
  • depression
  • hearing loss
  • periodontal disease
  • visual impairment
  • herpes simplex virus type 1 (HSV-1) infection
  • hyperlipidemia
  • female sex
  • elevated plasma homocysteine level
  • surgery under general anesthesia
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • cognitive testing
  • CBC
  • metabolic panel
  • serum thyroid-stimulating hormone (TSH)
  • serum vitamin B12
  • urine drug screen
  • CT brain (without contrast)
  • MRI brain (without contrast)
Detalhes completos

Investigações a serem consideradas

  • cerebrospinal fluid (CSF) analysis
  • serum rapid plasma reagin/Venereal Disease Research Laboratory (VDRL)
  • serum HIV testing
  • formal neuropsychological testing
  • genetic testing
  • fluorodeoxyglucose-PET (FDG-PET)
  • CSF biomarker testing
Detalhes completos

Novos exames

  • amyloid-PET
  • blood biomarkers

Algoritmo de tratamento

CONTÍNUA

all patients

Colaboradores

Autores

Judith Neugroschl, MD

Associate Professor of Psychiatry

Alzheimer's Disease Research Center

Icahn School of Medicine at Mount Sinai

New York

NY

Declarações

JN participates in research funded by two National Institutes for Health (NIH) grants. She is funded by the Alzheimer's Disease Research Center: one grant funds the center’s Alzheimer disease research, and the other is a training grant to encourage new colleagues from disadvantaged backgrounds to consider Alzheimer disease research as a career.

Agradecimentos

Dr Judith Neugroschl would like to gratefully acknowledge Dr Brandy R. Matthews, Dr Asif S. Bhutto, and Dr Julie K. Gammack, the previous contributors to this topic.

Declarações

BRM, ASB, and JKG declare that they have no competing interests.

Revisores

Roy J. Goldberg, MD, FACP, AGSF, CMD

Medical Director

Kings Harbor Multicare Center

New York

NY

Declarações

RJG declares that he has no competing interests.

Philip Scheltens, MD, PhD

Professor of Neurology

Department of Neurology/Alzheimer Center

VU University Medical Center

Amsterdam

The Netherlands

Declarações

PS declares that he has no competing interests.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission. Lancet. 2024 Aug 10;404(10452):572-628. Resumo

American College of Radiology. ACR appropriateness criteria: dementia. 2024 [internet publication].Texto completo

McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;(3):CD003154.Texto completo  Resumo

Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 Sep 22;(9):CD001191.Texto completo  Resumo

Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018 Jun 18;(6):CD001190.Texto completo  Resumo

Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May 1;173(5):543-6.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Diagnósticos diferenciais

    • Delirium
    • Depression
    • Vascular dementia
    Mais Diagnósticos diferenciais
  • Diretrizes

    • ACR appropriateness criteria: dementia
    • European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
    Mais Diretrizes
  • Patient information

    Alzheimer disease and other kinds of dementia

    Caring for someone with dementia

    More Patient information
  • Calculators

    Geriatric Depression Scale

    More Calculators
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer